US2023226141A1PendingUtilityA1

Angiotensin ii alone or in combination for the treatment of hypotension

84
Assignee: THE GEORGE WASHINGTON UNIV A CONGRESSIONALLY CHARTERED NOT FOR PROFIT CORPORATIONPriority: Dec 18, 2013Filed: Jan 23, 2023Published: Jul 20, 2023
Est. expiryDec 18, 2033(~7.4 yrs left)· nominal 20-yr term from priority
Inventors:Lakhmir Chawla
A61K 38/085A61K 31/137A61K 9/0019A61P 9/02A61K 31/135A61P 43/00A61K 2300/00
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a human patient suffering from low blood pressure, comprising administering angiotensin II to the patient at an initial rate of about 20 ng/kg/min and titrating the rate down. 
     
     
         2 . The method of  claim 1 , wherein the rate is titrated down to about 15 ng/kg/min. 
     
     
         3 . The method of  claim 1 , wherein the rate is titrated down to about 10 ng/kg/min. 
     
     
         4 . The method of  claim 1 , wherein the rate is titrated down to about 5 ng/kg/min. 
     
     
         5 . The method of  claim 1 , wherein the rate is titrated down to about 1.25 ng/kg/min. 
     
     
         6 . The method of  claim 1 , wherein the patient has shock, distributive shock, cardiogenic shock, sepsis, or acute kidney injury. 
     
     
         7 . The method of  claim 1 , wherein the angiotensin II is administered to the patient at a rate sufficient to achieve and/or maintain a mean arterial pressure (MAP) of 65 mm Hg or above. 
     
     
         8 . The method of  claim 1 , wherein the angiotensin II consists of the sequence of SEQ ID NO: 1. 
     
     
         9 . A method of achieving target mean arterial pressure (MAP) of at least about 65 mmHg in a human patient experiencing low blood pressure, comprising administering angiotensin II to the patient at an initial rate of about 20 ng/kg/min and titrating the rate down. 
     
     
         10 . The method of  claim 9 , wherein the rate is titrated down to about 15 ng/kg/min. 
     
     
         11 . The method of  claim 9 , wherein the rate is titrated down to about 10 ng/kg/min. 
     
     
         12 . The method of  claim 9 , wherein the rate is titrated down to about 5 ng/kg/min. 
     
     
         13 . The method of  claim 9 , wherein the rate is titrated down to about 1.25 ng/kg/min. 14, The method of  claim 9 , wherein the patient has shock, distributive, shock, cardiogenic shock, sepsis, or acute kidney injury. 
     
     
         15 . The method of  claim 9 , wherein the angiotensin II consists of the sequence of SEQ ID NO: 1. 
     
     
         16 . A method of treating a human patient suffering from low blood pressure, comprising administering angiotensin II to the patient at an initial rate of about 0.25 to 10 ng/kg/min and titrating the rate up or down. 
     
     
         17 . The method of  claim 16 , wherein the rate is titrated up to about 20 ng/kg/min. 
     
     
         18 . The method of  claim 16 , wherein the rate is titrated up to about 30 ng/kg/min. 
     
     
         19 . The method of  claim 16 , wherein the rate is titrated up to about 40 ng/kg/min. 
     
     
         20 . The method of  claim 16 , wherein the rate is titrated down to about 5 ng/kg/min. 
     
     
         21 . The method of  claim 16 , wherein the rate is titrated down to about 1.25 ng/kg/min. 
     
     
         22 . The method of  claim 16 , wherein the patient has shock, distributive shock, cardiogenic shock, sepsis, or acute kidney injury. 
     
     
         23 . The method of  claim 16 , wherein the angiotensin II consists of the sequence of SEQ ID NO: 1. 
     
     
         24 . A method of achieving target mean arterial pressure (MAP) of at least about 65 mmHg in a human patient experiencing low blood pressure, comprising administering angiotensin II to the patient at an initial rate of about 0.25 to 10 ng/kg/min and titrating the rate up or down. 
     
     
         25 . The method of  claim 24 , wherein the dose is titrated up to about 30 ng/kg/min. 
     
     
         26 . The method of  claim 24 , wherein the dose is titrated up to about 40 ng/kg/min. 
     
     
         27 . The method of  claim 24 , wherein the rate is titrated down to about 5 ng/kg/min. 
     
     
         28 . The method of  claim 24 , wherein the rate is titrated down to about 1.25 ng/kg/min. 
     
     
         29 . The method of  claim 24 , wherein the patient has shock, distributive shock, cardiogenic shock, sepsis, or acute kidney injury. 
     
     
         30 . The method of  claim 24 , wherein the angiotensin II consists of the sequence of SEQ ID NO: 1.

Join the waitlist — get patent alerts

Track US2023226141A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.